# Renal Denervation After USA FDA Approval: An Update from an Interventional Cardiologist’s Perspective

## TL;DR

This paper discusses the FDA approval of renal denervation for hypertension and the current challenges in its adoption and coding in the U.S.

## Contribution

The paper provides an updated analysis of renal denervation from an interventional cardiologist's viewpoint post-FDA approval.

## Key findings

- The FDA approved two renal denervation systems in late 2023 for hypertension treatment.
- The CPT panel rejected new coding for renal denervation in September 2024.
- The paper reviews clinical evidence and challenges in implementing RDN in practice.

## Abstract

In late 2023, the U.S. Food and Drug Administration (FDA) approved two renal denervation (RDN) systems for the treatment of hypertension. Several professional societies, including the Society of Cardiovascular Angiography and Intervention (SCAI), the American Heart Association (AHA), and numerous European associations, have recognized the potential role of RDN in managing hypertension. Despite widespread enthusiasm from clinicians, patients, and the industry, the American Medical Association’s Current Procedural Terminology (CPT) panel rejected the introduction of new codes for renal denervation at its September 2024 meeting. This article analyzes the latest evidence from clinical trials and registries, reviews current challenges in clinical practice, and explores the role of contemporary hypertension treatment from the perspective of interventional cardiologists.